Clinical Core

临床核心

基本信息

批准号：
10622636
负责人：
JOHN MORRIS
金额：
$ 150.06万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-15 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10622636
关键词：
Address Adult African American African American population Age Aliquot Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Amyloid Amyloid beta-42 Area Autopsy Behavioral Biological Assay Biological Markers Blood Brain Caring Circadian Rhythms Clinical Clinical assessments Cognitive Communities DNA Data Data Set Dementia Dermal Development Disease Eligibility Determination Enrollment Ensure Etiology Fibroblasts Funding Genetic Glycosylated hemoglobin A Grant Heterogeneity Image Impaired cognition Individual Infrastructure Life Cycle Stages Liquid substance Longitudinal Studies Measures Minority Nature Neurodegenerative Disorders Neurologic Neuropsychology Nuclear Pore Complex Participant Plasma Population Population Heterogeneity Positron-Emission Tomography Procedures Protocols documentation Psychometrics Research Research Personnel Research Priority Research Project Grants Resources Risk Sampling Scientist Severities Sex Differences Sleep Third-Party Payer Training Vascular Dementia aging brain brain magnetic resonance imaging cognitive function cognitive testing cohort data exchange data management education research induced pluripotent stem cell informant instrument metropolitan mild cognitive impairment molecular phenotype neuropathology normal aging novel novel strategies outreach pre-clinical programs racial difference recruit repository statistics tau Proteins tau-1 tool

项目摘要

Core B: Clinical Project Summary Core B: Clinical recruits, assesses, and follows all participants in the Knight ADRC Cohort. It uses well- established informant-based clinical and psychometric instruments (including the Uniform Data Set) at entry and annually thereafter to obtain clinical, cognitive, behavioral, and neurological data to carefully characterize each participant as to the presence or absence of dementia and, when present, its severity and etiology. The Core has successfully functioned to serve the needs of cutting-edge research projects of the Knight ADRC and its affiliated grants since its inception in 1985 and will continue to do so in the next 5-year funding period. The Core's Specific Aims in the proposed funding period are: 1. Maintain an current active cohort of participants (current N=272), carefully characterized as to the presence or absence of symptomatic AD, to support longitudinal studies of the clinical, cognitive, and biomedical correlates of symptomatic AD in comparison with cognitively normal aging and to mark the transition of participants with preclinical AD to cognitive impairment. 2. Annually enroll and assess 40 new participants age 65y or older (50y or older for symptomatic individuals), to replenish attritional losses and expand the active cohort to ~350. 3. Collect data, images, and biospecimens (DNA, CSF, plasma, dermal fibroblasts, and iPSCs) from participants as appropriate. 4. Solicit brain autopsy from all participants. 5. Continue to engage individuals in the African American community in St. Louis to promote the inclusion of African Americans in research. 6. In conjunction with the Research Education Component, use Core resources to train early stage investigators in dementia assessment, the heterogeneity of ADRD, and clinicopathological correlations that explore the multifactorial nature of AD. 7. Continue to ensure the broad sharing of Knight ADRC tools, data, and biospecimens and continue contributions to multicenter ADRD programs. 8. Address appropriate NAPA milestones related to cognitive data, longitudinal molecular phenotyping, sex and racial differences, sleep, and vascular contributions to dementia.

核心 B：临床项目总结核心 B：临床招募、评估和跟踪 Knight ADRC 队列中的所有参与者。它用得好—— 在输入时建立基于信息提供者的临床和心理测量工具（包括统一数据集）此后每年获取临床、认知、行为和神经学数据，以仔细表征每位参与者是否患有痴呆症，如果存在，其严重程度和病因。这 Core 已成功满足 Knight ADRC 尖端研究项目的需求其附属赠款自 1985 年成立以来，并将在下一个 5 年资助期内继续这样做。这核心在拟议资助期内的具体目标是： 1. 维持当前活跃的参与者队列（当前 N=272），仔细描述其存在情况或不存在症状性 AD，以支持临床、认知和生物医学的纵向研究与认知正常衰老相比，有症状的 AD 具有相关性，并标记 AD 的转变患有临床前 AD 认知障碍的参与者。 2. 每年招募并评估 40 名 65 岁或以上的新参与者（有症状的个体为 50 岁或以上），补充人员流失并将活跃队列扩大至约 350 人。 3. 收集数据、图像和生物样本（DNA、CSF、血浆、真皮成纤维细胞和 iPSC）适当的参与者。 4. 征求所有参与者的脑部尸检。 5. 继续让圣路易斯非裔美国人社区的个人参与进来，以促进包容从事研究的非裔美国人。 6. 结合研究教育部分，利用核心资源进行早期培训痴呆症评估、ADRD 的异质性以及临床病理学相关性的研究人员探索 AD 的多因素性质。 7. 继续确保 Knight ADRC 工具、数据和生物样本的广泛共享，并继续对多中心 ADRD 项目的贡献。 8. 解决与认知数据、纵向分子表型、性别相关的适当 NAPA 里程碑以及种族差异、睡眠和血管对痴呆症的影响。